Revolutionizing Drug Discovery with AI Technology
In an exciting development for the pharmaceutical industry, Recursion (NASDAQ: RXRX), a prominent TechBio company focused on decoding biology, has announced a groundbreaking collaboration with Enamine. This partnership aims to create screening libraries by leveraging cutting-edge AI and machine learning technologies, specifically utilizing the Recursion OS alongside Enamine's extensive REAL Space, known as the largest collection of make-on-demand small molecules.
Introduction to the Collaboration
Together, these two innovative companies have curated an impressive collection of 10 enriched screening libraries, encompassing over 15,000 newly synthesized compounds. Designed specifically to enhance drug discovery efforts, these libraries target 100 key drug areas that are often challenging in the biological realm.
Understanding Enamine's REAL Space
Enamine's REAL Space represents a unique achievement in the chemical library landscape, accumulating insights from millions of parallel synthetic processes. Despite the vast potentials of chemical space, accessing the most relevant compounds can be daunting due to the overwhelming number of options—totaling in the tens of billions. The partnership between Recursion and Enamine aims to streamline this process by fusing the expansive chemical data with Recursion's predictive capabilities to identify small molecule compatibility with specific protein targets.
Benefits of the Collaboration
Chris Gibson, Co-Founder and CEO of Recursion, emphasized the significance of this collaboration, stating, "We have been using the Recursion OS to identify compounds across Enamine’s vast chemical space for our own internal discovery needs. This collaboration allows us to extend that approach to areas of biology that are of general interest to the industry." The joint effort represents a fusion of Enamine's vast library and Recursion's AI-driven drug discovery methodologies, which aims to enhance the efficiency of drug development processes.
The Future of Drug Discovery
These curated compound libraries are the result of ongoing research efforts between Recursion and Enamine. By gaining access to tens of thousands of compounds that Recursion predicts may interact with underexplored biological functions, the partnership not only aids their internal research but also extends the commercial potential for both entities.
Leveraging Advanced Technologies
Andrey Tolmachov, CEO and Founder of Enamine, noted the transformative potential of Enamine's REAL Space. Although it has previously found applications in ultra-large virtual screening campaigns, it has yet to be explored at substantial scales across various biological targets. Tolmachov remarked, "Our partnership with Recursion allows us to tap into their cutting-edge technology to rapidly uncover novel compounds with high potential in multiple research fields." This collaboration aims to introduce a new era of compound libraries that can significantly support hit-finding campaigns, accelerated by direct access to analogues from the REAL library.
About Recursion and Its Impact on Medicine
Founded with a mission to decode biology, Recursion (NASDAQ: RXRX) is at the forefront of transforming the landscape of drug discovery. The company builds on its proprietary platform, the Recursion OS, to unravel one of the world’s largest biological and chemical datasets. By employing sophisticated machine learning algorithms, Recursion confidently distills trillions of searchable relationships across biology and chemistry, devoid of human biases.
The Scale of Recursion's Operations
Operating one of the most powerful supercomputers globally, Recursion harnesses experimental power unmatched in the industry—conducting millions of wet lab experiments weekly. With headquarters in Salt Lake City and multiple offices across North America and Europe, Recursion embodies innovation and commitment in the life sciences field.
About Enamine's Unique Offerings
Enamine stands out as an integrated discovery Contract Research Organization, uniquely positioned to explore new chemical spaces. Boasting access to a vast array of compounds, Enamine also provides a comprehensive platform of services designed to enhance drug discovery processes. Their REAL Space contains an astonishing 64.9 billion make-on-demand molecules, which can be synthesized rapidly and economically—offering tremendous prospects for drug developers.
Contact Information
For further inquiries regarding the collaboration or the curated compound libraries, interested parties can reach out to:
Yurii Moroz, PhD
VP of Sales and Marketing, Enamine
y.moroz@enamine.net
https://enamine.net
Frequently Asked Questions
What is the main goal of the partnership between Recursion and Enamine?
The partnership aims to create targeted compound libraries that enhance drug discovery efforts by leveraging advanced AI and machine learning technologies.
How do the curated compound libraries enhance drug discovery?
These libraries are designed to accelerate the identification of small molecules that can effectively interact with key biological targets.
What is the significance of Enamine's REAL Space?
The REAL Space offers a vast collection of make-on-demand molecules, providing unprecedented possibilities for compound synthesis and discovery without the usual limitations.
How does Recursion leverage its technology?
Recursion utilizes its comprehensive dataset and machine learning algorithms to predict small molecule compatibility, aiding in the efficient selection of drug candidates.
Where is Recursion headquartered?
Recursion's headquarters is located in Salt Lake City, Utah, with additional offices in various major cities including New York and London.
